Levantilides A and B, 20-Membered Macrolides from a Micromonospora Strain Isolated from the Mediterranean Deep Sea Sediment

Andrea Gärtner, Birgit Ohlendorf, Dirk Schulz, Heidi Zinecker †, Jutta Wiese and Johannes F. Imhoff *

Kieler Wirkstoff-Zentrum (KiWiZ) at the IFM-GEOMAR (Leibniz Institute of Marine Sciences), Am Kiel-Kanal 44, 24106 Kiel, Germany; E-Mails: agaertner@ifm-geomar.de (A.G.); bohlendorf@ifm-geomar.de (B.O.); dschulz@ifm-geomar.de (D.S.); heidi.zinecker@uni-bonn.de (H.Z.); jwiese@ifm-geomar.de (J.W.)

† Present address: Universität Bonn, Pharmazeutisches Institut, Pharmazeutische Chemie I, An der Immenburg 4, 53121 Bonn, Germany.

* Author to whom correspondence should be addressed; E-Mail: jimhoff@ifm-geomar.de; Tel.: +49-431-600-4450; Fax: +49-431-600-4452.

Received: 22 November 2010; in revised form: 22 December 2010 / Accepted: 13 January 2011 / Published: 14 January 2011

**Abstract:** Two new 20-membered macrolides, levantilide A and B, were isolated from the Micromonospora strain M71-A77. Strain M71-A77 was recovered from an Eastern Mediterranean deep-sea sediment sample and revealed to produce the levantilides under in situ salinity of 38.6‰. The chemical structures of the levantilides were elucidated on the basis of different one- and two-dimensional NMR experiments. Levantilide A exhibits a moderate antiproliferative activity against several tumor cell lines.

**Keywords:** macrolide; Micromonospora; deep sea; natural product; marine

1. Introduction

The deep sea is an extreme environment which is still marginally investigated and harbors a great variety of bacteria that have, so far, not been cultivated. Bacteria which live in the deep sea need to adapt to the specific environmental characteristics such as high hydrostatic pressure, low temperature and only occasional nutrient supply. These constraints quite likely determine the phylogenetic
diversity of the deep-sea bacterial communities and also affect the secondary metabolite production of these bacteria. Therefore, deep-sea bacteria are considered as a promising source for the discovery of new natural products. Marine members of Actinobacteria are highly potent producers of interesting compounds [1–5] as was already shown for their terrestrial counterparts [6]. Only recently, two strains of Streptomyces sp. from the Atlantic ocean deep-sea sediment were shown to produce the two new natural products caboxamycin and albidopyrone [7,8].

With special focus on the discovery of new natural products, we selectively isolated Actinobacteria from the deep-sea sediment of the Eastern Mediterranean Sea (the so-called Levantine Sea). This environment is characterized by a relatively high bottom temperature of 13–14 °C, salinity values of approximately 38–39‰, high hydrostatic pressure (440 bar at the sampling site) and an extreme depletion of nutrients [9]. Among the isolated bacteria, strain M71-A77 produced two new macrolides named levantilides A (1) and B (2), which will be described in this paper.

2. Results and Discussion

Strain M71-A77 was isolated from the Eastern Mediterranean deep-sea sediment (4400 m) and revealed 99.3% 16S rRNA gene sequence similarity to Micromonospora auratinigra DSM 44815T (AB159779). Analyses of the culture extract of this strain (incubated in liquid soja-peptone medium) by HPLC-DAD-MS led to the detection of two unknown 20-membered macrolides, levantilide A (1) and B (2), with detected masses of m/z 508 and m/z 506, respectively. Subsequent cultivation of the strain in larger scale (10 L) led to the isolation of the levantilides as colorless solids.

Levantilide A (1) R = –OH  
Levantilide B (2) R = =O

Levantilide A (1) had a measured molecular mass of m/z 531.3676 [M + Na]+ (calculated for C30H52NaO6 531.3656), which yielded the molecular formula C30H52O6 and implied five degrees of unsaturation. The structure elucidation of the compound was mainly based on one- and two-dimensional NMR spectra of 1. The respective 13C NMR spectrum displayed 30 distinct signals (Table 1) which were consistent with the deduced molecular formula. The carbon resonances gave evidence of one carbonyl carbon (δC 166.1 ppm), one olefinic quaternary carbon (δC 132.8 ppm), five olefinic methine carbons (δC 120.4 ppm to 143.8 ppm), five methine carbons adjacent to oxygen atoms (δC 67.2 ppm to 77.4 ppm), four further methine carbons (δC 29.4 ppm to 41.0 ppm), eight methylene groups (δC 22.0 ppm to 40.9 ppm) and six methyl groups (δC 10.1 ppm to 21.5 ppm). The HSQC spectrum allowed all carbon resonances to be unambiguously assigned to the resonances of their
directly attached protons. The final planar structure of the molecule was deduced from COSY and HMBC spectra (Figure 1). With a shift of 166.1 ppm, the carbonyl carbon C-1 was very likely to belong to a conjugated ester function. HMBC correlations from H-3 (δH 7.06) and H-2 (δH 5.78) identified the adjacent methine groups. H-2 to H-5 (δH 6.08) were all olefinic protons which coupled to each other. H-5 showed HMBC correlations to C-3 (δC 143.8) as well as to C-6 (δC 39.6), a methylene carbon, and C-7 (δC 67.2), a hydroxylated methine. H-7 (δH 3.98) showed COSY correlations to H-6 as well as to the methylene group CH2-8 (δC 33.4, δH 1.51; 1.16). Next to CH2-8, there followed four methine groups, CH-9 to CH-12, each of them substituted with either a hydroxy group, CH-9 (δC 67.4, δH 3.92) and CH-11 (δC 75.3; δH 2.98), or a methyl group, CH-10 (δC 41.0; δH 1.68) and CH-12 (δC 32.1 and δH 1.24), which could be unequivocally proven by their shifts, COSY and HMBC correlations. Not only did the COSY correlations of the methyl groups CH3-29 (δC 17.7 and δH 0.58) and CH3-30 (δC 11.1 and δH 0.86) connect them to the methine groups CH-12 and CH-10, but their HMBC correlations also gave further evidence of the positions of the neighboring carbons and secured the sequence from CH-9 to CH-12. Furthermore, a methylene group CH2-13 (δC 40.1, δH 1.87 and 1.51) was shown to connect the methine groups CH-9 to CH-12 to the quaternary olefinic carbon C-14 (δC 132.8). Therefore, the last double bond evidently was located between C-14 and C-15 (δC 132.7). The corresponding proton H-15 (δH 4.76) showed long range couplings to C-17 (δC 40.9), C-13, C-16 (δC 29.4), C-27 (δC 21.5) and C-28 (δC 17.0) and coupled to H-16 and H-2-13. CH2-17 (δH 1.34 and 1.05) formed the junction between the methyl-bearing methines CH-16 and CH-18 as indicated by HMBC correlations from H-17 to C-18 (δC 33.4), C-26 (δC 17.5) and C-27. The substructure was further supported by COSY correlations of the same proton signal (H-17) to the resonances of H-16 (δH 2.59) and H-18 (δH 1.75). CH-19 (δC 77.4; δH 4.71), the methine adjacent to CH-18, closed the macrolide ring as proven by its HMBC correlation to C-1 and connected it to the side chain of the molecule by correlations to the methylene groups CH2-20 (δC 27.9; δH 1.52 and 1.47) and CH2-21 (δC 22.0; δH 1.30). After the carbonyl group and the three double bonds, one degree of unsaturation still had to be accounted for, which was accomplished by the closure of the ring. Analysis of the NMR spectra gave evidence of a 3-hydroxy-hexyl-side chain. All double bonds, Δ2,3, Δ4,5 and Δ14,15, were determined to be E-configured. For the double bonds Δ2,3 and Δ4,5, the configuration was deduced from the 3J coupling constants of approximately 15 Hz. Δ14,15 is a trisubstituted double bond, therefore the NOESY spectrum had to be consulted. As H-15 showed NOESY-correlations to H-2-13, but not to H3-28, this double bond, too, had to be E-configured. Thus, the planar structure of levantilide A could be unambiguously delineated from the spectroscopic data.

The derivative, levantilide B (2), showed a mass difference of 2 amu in the HPLC-DAD-MS measurement, which indicated one additional double bond, which for example can be observed, when a hydroxy-group is replaced by a carbonyl function, as it was the case here. Already in the 1H NMR spectrum it was obvious that all signals belonging to protons of the macroline ring were identical in both molecules (see Table 2). However, significant differences could be observed for the signals of the side chain. Analysis of the data showed that the methine group CH-23 was no longer present in levantilide B. Instead of it, an additional signal of a carbonyl carbon appeared, its shift of 210.5 ppm proving it to be a ketone. As a consequence of the presence of a carbonyl group instead of a methine in position 23, the signal of H2-24 was no longer a multiplet, but appeared as a quartet as it only coupled with the methyl group CH3-25. Thus, the planar structure of 2 was established as depicted.
| position | δC  | δH, J [Hz] | COSY | HMBC | NOESY |
|----------|------|------------|------|------|-------|
| 1        | 166.1, C |            |      |      |       |
| 2        | 120.4, CH | 5.78, d (15.5) | 3    | 1, 3, 4, 5 | 3, 4 |
| 3        | 143.8, CH | 7.06, dd (11.2, 15.5) | 2, 4 | 1, 2, 4, 5 | 2, 4, 5 |
| 4        | 130.6, CH | 6.29, dd (11.2, 15.2) | 3, 5 | 2, 3, 6 | 2, 3, 5, 6b |
| 5        | 139.8, CH | 6.08, ddd (4.4, 10, 15.2) | 4, 6 | 3, 6, 7 | 3, 4, 6a, 7 |
| 6a       | 39.6, CH₂ | 2.57, m | 5, 6b, 7 | 4, 5, 7, 8 | 5 |
| 6b       | 2.33, dt (14.4, 9.9) | 5, 6a, 7 | 4, 5, 7, 8 | 4 |
| 7        | 67.2, CH | 3.98, m | 6, 7-OH, 8 | 8b, 5 |
| 7-OH     | 4.81, br. d (3.8) | 7 | 7, 8 |
| 8a       | 33.4, CH₂ | 1.51a, m | 7, 8b, 9 | 6, 7, 9 | 8b |
| 8b       | 1.16, ddd (14.6, 5.6, 2.3) | 7, 8a, 9 | 6, 7, 9 | 7, 8a, 11 |
| 9        | 67.4, CH | 3.92, br. d (11.2) | 8, 9-OH, 10 | 30 | 12 |
| 9-OH     | 4.63, br. s | 9 | 8, 9, 10 |
| 10       | 41.0, CH | 1.68, m | 9, 11, 30 |      |       |
| 11       | 75.3, CH | 2.98 br. ddd (8.9, 6.0, 1.8) | 10, 11-OH, 12 | 9, 10, 12, 13, 29, 30 | 8b, 29 |
| 11-OH    | 4.00, d (6.0) | 11 | 10, 11, 12 |      |       |
| 12       | 32.1, CH | 1.24, m | 11, 13, 29 | 9 |       |
| 13a      | 40.1, CH₂ | 1.87, br. d (12.8) | 12, 13b, 15, 29 | 11, 12, 14, 15, 27, 28, 29 | 13b |
| 13b      | 1.51a, m | 12, 13a, 15, 29 | 11, 12, 14, 15, 27, 28, 29 | 13a, 15 |
| 14       | 132.8, C |            |      |      |       |
| 15       | 132.7, CH | 4.76, d (7.8) | 13, 16 | 12, 13, 16, 17, 27, 28 | 13b, 17, 29 |
| 16       | 29.4, CH | 2.59, m | 15, 17, 27 | 14, 17, 27 | 27, 28 |
| 17a      | 40.9, CH₂ | 1.34, m | 16, 17b, 18 | 15, 16, 18, 19, 26, 27 | 17b |
| 17b      | 1.05, ddd (13.5, 8.7, 5.0) | 16, 17a, 18 | 15, 16, 18, 19, 26, 27 | 17a, 27 |
| 18       | 33.4, CH | 1.75, m | 17, 19, 26 | 16, 17, 19, 20, 26 |      |
| 19       | 77.4, CH | 4.71, dt (10, 2.4) | 18, 20 | 1, 17, 20, 21,26 | 21, 26 |
| 20a      | 27.9, CH₂ | 1.52a, m | 19, 21 |      |       |
| 20b      | 1.47a, m | 19, 21 |      |      |       |
| 21       | 22.0, CH₂ | 1.30b, m | 20 | 19 |       |
| 22       | 36.1, CH₂ | 1.31b, m | 23 | 23, 23-OH |       |
| 23       | 70.8, CH | 3.28, m | 22, 23-OH, 24 | 21, 22, 25 | 22, 25, 26 |
| 23-OH    | 4.25, d (5.2) | 23 | 22, 23, 24 | 22, 26 |       |
| 24a      | 29.7, CH₂ | 1.30b, m | 23, 25 | 25 |       |
| 24b      | 1.27b, m | 23, 25 | 25 |      |       |
| 25       | 10.1, CH₃ | 0.82, t (7.4) | 24 | 23, 24 | 23, 24 |
| 26       | 17.5, CH₃ | 0.88, d (6.2) | 18 | 17, 18, 19 | 19, 23, 23-OH |
| 27       | 21.5, CH₃ | 0.84, d (6.8) | 16 | 15, 16, 17 | 16, 17b |
| 28       | 17.0, CH₃ | 1.53a, s | 13, 14, 15 | 16 |       |
| 29       | 17.7, CH₃ | 0.58, d (6.7) | 12 | 11, 12, 13 | 11, 15 |
| 30       | 11.1, CH₃ | 0.86, d (5.9) | 10 | 9, 10, 11 | 9, 11 |

ᵃᵇ signals are overlapping.
Figure 1. Selected HMBC correlations relevant for the structure elucidation of 1.

Table 2. NMR spectroscopic data of the levantilides in acetone-$d_6$ (500 MHz).

|          | levantilide A (1) |        | levantilide B (2) |        |
|----------|-------------------|--------|-------------------|--------|
| 1        | 166.9             | 166.9  |                   |        |
| 2        | 122.0             | 5.83   | 121.9             | 5.83   |
| 3        | 144.3             | 7.14   | 144.4             | 7.15   |
| 4        | 131.9             | 6.36   | 131.9             | 6.36   |
| 5        | 140.1             | 6.09   | 140.2             | 6.11   |
| 6a       | 40.6              | 2.69   | 40.6              | 2.66   |
| 6b       |                   | 2.47   |                   | 2.46   |
| 7        | 69.3              | 4.11   | 69.4              | 4.10   |
| 8a       | 33.8              | 1.73   | 33.9              | 1.72   |
| 8b       |                   | 1.34   |                   | 1.34   |
| 9        | 69.3              | 4.18   | 69.4              | 4.17   |
| 10       | 42.2              | 1.86   | 42.3              | 1.86   |
| 11       | 77.4              | 3.17   | 77.4              | 3.18   |
| 12       | 33.2              | 1.41   | 33.3              | 1.41   |
| 13a      | 41.4              | 2.00   | 41.4              | 1.99   |
| 13b      |                   | 1.69   |                   | 1.69   |
| 14       | 134.1             |        | 134.1             |        |
| 15       | 134.1             | 4.86   | 134.1             | 4.87   |
| 16       | 30.7              | 2.70   | 30.7              | 2.69   |
| 17a      | 41.9              | 1.47   | 41.9              | 1.43   |
| 17b      |                   | 1.12   |                   | 1.11   |
| 18       | 34.7              | 1.87   | 34.7              | 1.87   |
| 19       | 78.8              | 4.83   | 78.6              | 4.81   |
| 20a      | 28.9              | 1.61   | 28.3              | 1.57   |
| 20b      |                   | 1.53   |                   | 1.50   |
| 21a      | 23.3              | 1.42   | 21.3              | 1.62   |
| 21b      |                   |        |                   | 1.47   |
| 22       | 37.6              | 1.42   | 42.1              | 2.45   |
| 23       | 72.7              | 3.42   | 210.5             |        |
| 24a      | 31.1              | 1.43   | 36.0              | 2.42   |
| 24b      |                   | 1.37   |                   |        |
| 25       | 10.4              | 0.90   | 8.0               | 0.96   |
| 26       | 18.6              | 0.91   | 18.4              | 0.91   |
| 27       | 22.0              | 0.86   | 21.8              | 0.87   |
Table 2. Cont.

|   | 28   | 17.6 | 1.62 | 17.6 | 1.63 |
|---|------|------|------|------|------|
| 29 | 18.5 | 0.70 | 18.4 | 0.71 |
| 30 | 10.8 | 0.98 | 11.0 | 0.98 |

The levantilides are macrolides with a 20-membered lactone ring. From a biosynthetic point of view macrolides are typical type I PKS products with very well studied biosynthetic pathways. From the structures of the levantilides, a very simple assembly of a propionate starter unit, five further propionate building blocks and altogether six acetate building blocks can be deduced.

Cytotoxicity tests of 1 revealed antiproliferative activities against gastric tumor cells GXF 251L (IC$_{50}$ = 40.9 µM), lung tumor cells LXFL 529L (IC$_{50}$ = 39.4 µM), mammary tumor cells MAXF 401NL (IC$_{50}$ = 28.3 µM), melanoma tumor cells MEXF 462NL (IC$_{50}$ = 48.6 µM), pancreas tumor cells PAXF 1657L (IC$_{50}$ = 20.7 µM) and renal tumor cells RXF 486L (IC$_{50}$ = 52.4 µM). Antimicrobial activity against the bacteria and fungi in the test panel were not observed for compounds 1 and 2.

Members of the *Actinomycetes* are well known to produce macrolide antibiotics [10]. Micromonospolides, mycinamincins, megalomicin, rosamicin and juvenimicins are e.g., macrolide antibiotics produced by members of the genus *Micromonospora*, but they all differ in the size of the macrolide ring from the levantilides [11–15]. The levantilides are 20-membered macrolides without an attached sugar and are, for example, related to the cytotoxic macrolides amphidinolide A and U [16,17] as well as to iriomoteolide 1a, b and c [18,19]. These compounds are also 20-membered macrolides which exhibit cytotoxic activity against several human tumor cell lines [20–22] and are produced by the marine symbiontic dinoflagellate *Amphidinium sp.* Iriomotolide 1a, 1b and 1c show remarkable cytotoxicity against B lymphocyte cells DG75 (IC$_{50}$ = 0.0039 µM, 1.7 µM and 0.0038 µM) while amphidinolide A and U possess cytotoxic activities against murein lymphoma cells L1210 (IC$_{50}$ = 3.7 µM and 10.7 µM) and against human epideromoid carcinoma cells (IC$_{50}$ = 10.7 µM and 35.08 µM).

According to Skropeta (2008), polyketide metabolites have been reported from all water depths, but interestingly only 8% of the marine natural products known so far are produced by organisms obtained at depth greater than 1000 m [23]. As a matter of course, this might be due to the fact that the deep sea is hardly accessible. In the present study, it was shown by cultivation of strain M71-A77 with habitat sea water (38.6%) that levantilides are also produced under the high salinity conditions occurring *in situ* in the Mediterranean Sea. Though strains of *Micromonospora* ssp. were frequently isolated from deep sea habitats [24–26], to the best of our knowledge the levantilides are the first natural products described from a *Micromonospora* sp. strain isolated from the deep sea.

3. Experimental Section

3.1. Isolation and identification of strain M71-A77

Strain M71-A77 has been isolated from a sediment core (1.5–5 cm sediment horizon) from 4400 m depth during a research cruise with RV Meteor M71/2 in the Eastern Mediterranean Sea, the so-called Levantine Sea [34° 25.48 N, 26° 05.39 E]. One gram of the sediment sample was transferred to a sterile petri dish and dried for 2 months at 20 °C prior to incubation for 1 h at 120 °C dry heat.
Sediment was then re-suspended in demineralized water and inoculated on agar plates of XJ4-medium containing 1 L of demineralized water 18 g agar, 0.1 g histidine, 1 g raffinose, 0.5 g sodium hydrogen phosphate, 1.7 g potassium chloride, 0.05 g magnesium sulfate, 0.01 g iron sulfate, 0.02 g calcium carbonate, 0.5 mg thiamine hydrogen chloride, 0.5 mg riboflavin, 0.5 mg niacin, 0.5 mg pirodixin, 0.5 mg calcium pantothenate, 0.5 mg inositol, 0.5 mg para aminobenzoic acid and 0.25 mg biotin. After 2 months of incubation at 28 °C, strain M71-A77 was isolated by transferring to fresh XJ4-medium. The strain was classified by 16S rRNA gene sequence analysis according to Gärtner et al. [27]. The 16S rRNA gene sequence was deposited in the EMBL Nucleotide Sequence Database and was assigned the accession no. FR714833.

3.2. Chemical analysis

**General experimental procedures.** The optical rotation was measured on a Perkin Elmer model 241 polarimeter. UV-spectra were obtained on a NanoVue (GE Healthcare). NMR spectra were recorded on a Bruker DRX500 spectrometer (500 and 125 MHz for $^1$H and $^{13}$C NMR, respectively), using the signals of the residual solvent protons and the solvent carbons as internal references ($\delta_H$ 2.04 and $\delta_C$ 28.9 ppm for acetone-$d_6$; $\delta_H$ 2.50 and $\delta_C$ 39.51 ppm for DMSO-$d_6$). High-resolution mass spectra were acquired on a benchtop time-of-flight spectrometer (MicrOTOF, Bruker Daltonics) with positive electrospray ionization. Analytical reversed phase HPLC-UV/MS experiments were performed using a C$_{18}$ column (Phenomenex Onyx Monolithic C18, 100×3.00 mm) applying an H$_2$O (A)/MeCN (B) gradient with 0.1% HCOOH added to both solvents (gradient: 0 min 5% B, 4 min 60% B, 6 min 100% B; flow 2 mL/min) on a VWR Hitachi Elite LaChrom system coupled to an ESI-ion trap detector (Esquire 4000, Bruker Daltonics). Preparative HPLC was carried out using a Phenomenex Gemini C18 110A AXIA, 100×50.00 mm column.

**Isolation of levantilides A and B.** 10 L of liquid starch-peptone medium (1L demineralized water 10 g starch, 5 g soja peptone, 15 g Tropic Marin® sea salt and 1 g calcium carbonate) were used for cultivation of strain M71-A77. After 8 days of incubation (28 °C, 125 rpm), the culture supernatant was separated from the cells by centrifugation at 10,000 rpm for 10 min (Beckman J2-MC). Cell pellets were suspended in methanol and homogenized three times with an Ultra Turax T25 basic (IKA-Werke GmbH & Co., Staufen, Germany) at 17,500 U/min for 1 min. After additional centrifugation, the methanol extract was decanted and dried. The culture broth supernatant was extracted with ethylacetate (1:1). The dried extracts were dissolved in methanol and analyzed by HPLC-UV/MS. Levantilides A and B were detected at 4.2 and 4.5 min with a maximum UV-absorption at 260 nm. For structure analysis, 1 and 2 were separated by reversed phase HPLC. For that purpose, HCOOH (0.1%) was added to the solvents H$_2$O (A) and MeCN (B) and a gradient from 10% B over 60% B (reached after 17 min) to 100% B was applied (flow 15 mL/min). Levantilides A and B were detected at 16.6 and 17.8 min. Thus, 7 mg of 1 and 3 mg of 2 were obtained.

**Levantilide A (1):** colorless, amorphous solid; [α]$^\text{20}_D$ –72.4 (c 0.145, MeOH); UV (MeOH) $\lambda_{\text{max}}$ (log ε) 262 (4.61); for 1D and 2D NMR data see Table 1 and SI; HRESIMS m/z 531.3676 [M + Na]$^+$ (C$_{30}$H$_{52}$NaO$_6$, 531.3656).
Levantilide B (2): colorless, amorphous solid; $[\alpha]_D^{20} -97.5$ (c 0.04, MeOH); UV (MeOH) $\lambda_{\text{max}}$ 261 (log ε) (4.48); $^1$H NMR (acetone-$d_6$, 500 MHz) δ 7.15 (1H, dd, J = 15.1, 11.0, H-3), 6.36 (1H, dd, J = 15.1, 11.0, H-4), 6.11 (1H, ddd, J = 15.1, 9.8, 4.4, H-5), 5.81 (1H, d, J = 15.1, H-2), 4.87 (1H, d, J = 8.0, H-15), 4.81 (1H, t, J = 10.2, 2.5, H-19), 4.17 (1H, dt, J = 11.9, 3.1, H-9), 4.10 (1H, m, H-7), 3.18 (1H, m, H-11) 2.69 (1H, m, H-16), 2.66 (1H, m, H-6a), 2.46 (1H, m, H-6b), 2.45 (2H, m, H$_2$-22), 2.42 (2H, q, J = 7.5, H$_2$-24), 1.99 (1H, m, H-13a), 1.87 (1H, m, H-18), 1.86 (1H, m, H-10), 1.72 (1H, ddd, J = 15.0, 11.2, 3.3, H-8a), 1.69 (1H, dd, J = 13.1, 10.9, H-13b), 1.63 (3H, s, H$_3$-28), 1.62 (1H, m, H-21a), 1.57 (1H, m, H-20a), 1.50 (1H, m, H-20b), 1.47 (1H, m, H-21b), 1.43 (1H, m, H-17a), 1.41 (1H, m, H-12), 1.34 (1H, d, J = 15.0, 5.4, 3.0, H-8b), 1.11 (1H, ddd, J = 14.6, 9.0, 5.1, H-17b), 0.98 (3H, d, J=7.0, H$_3$-30), 0.96 (3H, t, J = 7.5, H$_3$-25), 0.91 (3H, d, J = 7.5, H$_3$-26), 0.87 (3H, d, J = 7.0, H$_3$-27), 0.71 (3H, d, J = 7.0, H$_3$-29); for $^{13}$C NMR data see Table 2; HRESIMS m/z 529.3509 [M + Na]$^+$ (C$_{30}$H$_{50}$NaO$_6$, 529.3500).

3.3. Production of levantilide A (1) and B (2) at in situ salinity

Strain M71-A77 was tested for the production of secondary metabolites at habitat salinity (38.6 %). For that purpose, Tropical Marine® salt and aqua dest. were replaced by Mediterranean Sea water obtained from the sampling site. After 8 days of cultivation at 28 °C, the culture broth was extracted with ethylacetate and analyzed by analytical HPLC-UV/MS as described above.

3.4. Antimicrobial tests

Antimicrobial activity of compound 1 and 2 (100 µM) was tested against the Gram-positive bacteria Bacillus subtilis (DSM 347), Staphylococcus lentus (DSM 6672), the Gram-negative bacteria Xanthomonas campestris (DSM 2405), Escherichia coli (DSM 498), Erwinia amylovora (DSM 50901), Pseudomonas fluorescens (NCIMB 10586), Pseudomonas syringae (DSM 50252), Ralstonia solanacearum (DSM 9544), the yeast Candida glabrata (DSM 6425) and the fungus Septoria tritici as described by Lang et al. in 2007 [28]. The results were compared to a positive (100 µM chloramphenicol for bacteria and 100 µM cycloheximide for C. glabrata and S. tritici) and a negative (no compound) control on the same plate.

3.5. Cytotoxic tests

The in vitro antiproliferative activities of compound 1 against the gastric cancer cell line GXF 251L, lung cancer cell line LXFL 529L, melanoma cancer cell line MEXF 462NL, mammary cancer cell line MAXF 401NL, renal cancer cell line RXF 486L and pancreatic cancer cell line PAXF 1657L were determined by Oncotest GmbH (Freiburg, Germany) using a modified propidium iodide monolayer assay [29]. Compound 2 was not tested by Oncotest GmbH, for there was not enough left of the compound.

Acknowledgement

We thank G. Kohlmeyer-Yilmaz, M. Höftmann and F. Sönntichsen for running and processing NMR experiments at the Otto-Diels Institute of Organic Chemistry (Christian-Albrechts University of
Kiel, Germany). We also thank U. Drieling (Otto-Diels Institute of Organic Chemistry (Christian-Albrechts University of Kiel, Germany)) for giving us the opportunity and assisting us with the measurement of the optical rotation. The authors gratefully thank A. Erhard, S. Malien, K. Schumann, R. Koppe and R. Wicher\textsuperscript{f} for technical assistance. Thanks to J.B. Speakman from BASF for providing the strain \textit{S. tritici}. This study was performed at the Kieler Wirkstoff-Zentrum (KiWiZ) at the IFM-GEOMAR (Leibniz Institute of Marine Sciences). The KiWiZ is supported by the Ministry of Sciences, Economic Affairs and Transport of the State of Schleswig-Holstein (Germany) in the frame of the “Future Program for Economy” which is co-financed by the European Union (EFRE).

**Supplementary Information**

\(^1\)H NMR spectra, \(^13\)C NMR spectra, COSY spectra and HMBC spectra of compounds 1 and 2 as well as the NMR spectroscopic data of compound 2 are available as supplementary information.

**References**

1. Lam, K.S. Discovery of novel metabolites from marine actinomycetes. \textit{Curr. Opin. Microbiol.} \textbf{2006}, \textit{9}, 245–251.
2. Berdy, J. Bioactive microbial metabolites. \textit{J. Antibi.} \textbf{2005}, \textit{58}, 1–26.
3. Jensen, P.R.; Mincers, T.J.; Williams, P.G.; Fenical, W. Marine actinomycete diversity and natural product discovery. \textit{Antonie van Leeuwenhoek} \textbf{2005}, \textit{87}, 43–48.
4. Fiedler, H.P.; Bruntner, C.; Bull, A.T.; Ward, A.C.; Goodfellow, M.; Potterat, O.; Puder, C.; Mihm, G. Marine actinomycetes as a source of novel secondary metabolites. \textit{Antonie van Leeuwenhoek} \textbf{2005}, \textit{87}, 37–42.
5. Magarvey, N.A.; Keller, J.M.; Bernan, V.; Dworkin, M.; Sherman, D.H. Isolation and characterization of novel marine-derived actinomycete taxa rich in bioactive metabolites. \textit{Appl. Environ. Microbiol.} \textbf{2004}, \textit{70}, 7520–7529.
6. Bernan, V.S.; Greenstein, M.; Carter, G.T. Mining marine microorganisms as a source of new antimicrobials and antifungals. \textit{Curr. Med. Chem.-Anti-Infect. Agents} \textbf{2004}, \textit{3}, 181–195.
7. Hohmann, C.; Schneider, K.; Bruntner, C.; Irran, E.; Nicholson, G.; Bull, A.T.; Jones, A.L.; Brown, R.; Stach, J.E.M.; Goodfellow, M.; \textit{et al.} Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937\textsuperscript{*}. \textit{J. Antibi.} \textbf{2009}, \textit{62}, 99–104.
8. Hohmann, C.; Schneider, K.; Bruntner, C.; Brown, R.; Jones, A.L.; Goodfellow, M.; Kramer, M.; Imhoff, J.F.; Nicholson, G.; Fiedler, H.P.; \textit{et al.} Albidopyrane, a new [alpha]-pyrane-containing metabolite from marine-derived Streptomyces sp. NTK 227\textsuperscript{*}. \textit{J. Antibi.} \textbf{2009}, \textit{62}, 75–79.
9. Thingstad, T.F.; Krom, M.D.; Mantoura, R.F.C.; Flaten, G.A.F.; Groom, S.; Herut, B.; Kress, N.; Law, C.S.; Pasternak, A.; Pitta, P. Nature of phosphorus limitation in the ultraoligotrophic Eastern Mediterranean. \textit{Science} \textbf{2005}, \textit{309}, 1068–1071.
10. Katz, L.; Ashley, G.W. Translation and protein synthesis: macrolides. \textit{Chem. Rev.} \textbf{2005}, \textit{105}, 499–528.
11. Ohta, E.; Ohta, S.; Kubota, N.K.; Suzuki, M.; Ogawa, T.; Yamasaki, A.; Ikekami, S. Micromonospolide A, a new macrolide from Micromonospora sp. *Tetrahedron Lett.* **2001**, *42*, 4179–4181.

12. Weinstein, M.J.; Wagman, G.H.; Marquez, J.A.; Testa, R.T.; Oden, E.; Waitz, J.A. Megalomicin, a new macrolide antibiotic complex produced by Micromonospora. *J. Antibiot.* **1969**, *22*, 253–258.

13. Hatano, K.; Higashide, E.; Shibata, M. Studies on juvenimicin, a new antibiotic I. *J. Antibiot.* **1976**, *29*, 1163–1170.

14. Sato, S.; Muto, N.; Hayashi, M.; Fujii, T.; Otani, M. Mycinamicins, new macrolide antibiotics. I. *J. Antibiot.* **1980**, *33*, 364–376.

15. Waitz, J.A.; Drube, C.G.; Moss, E.L.; Weinstein, M.J. Biological studies with rosamicin, a new micromonospora-produced macrolide antibiotic. *J. Antibiot.* **1972**, *25*, 647–652.

16. Kobayashi, J.; Ishibashi, M.; Nakamura, H.; Ohizumi Terufumi, Y. Amphidinolide-A, a novel antineoplastic macrolide from the marine dinoflagellate sp. *Tetrahedron Lett.* **1986**, *27*, 5755–5758.

17. Tsuda, M.; Endo, T.; Kobayashi, J. Amphidinolide U, novel 20-membered macrolide from marine dinoflagellate amphidinium sp. *Tetrahedron* **1999**, *55*, 14565–14570.

18. Tsuda, M.; Oguchi, K.; Iwamoto, R.; Okamoto, Y.; Fukushima, E.; Kawabata, J.; Ozawa, T.; Masuda, A.; Kitaya, Y.; Omasa, K. Iriomoteolide-1a, a potent cytotoxic 20-membered macrolide from a benthic dinoflagellate Amphidinium species. *J. Org. Chem.* **2007**, *72*, 4469–4474.

19. Tsuda, M.; Oguchi, K.; Iwamoto, R.; Okamoto, Y.; Fukushima, E.; Kawabata, J.; Ozawa, T.; Masuda, A. Iriomoteolides-1b and -1c, 20-membered macrolides from a marine dinoflagellate Amphidinium species. *J. Nat. Prod.* **2007**, *70*, 1661–1663.

20. Kobayashi, J.; Tsuda, M. Amphidinolides, bioactive macrolides from symbiotic marine dinoflagellates. *Nat. Prod. Rep.* **2004**, *21*, 77–93.

21. Kobayashi, J.; Ishibashi, M. Bioactive metabolites of symbiotic marine microorganisms. *Chem. Rev.* **1993**, *93*, 1753–1769.

22. Kobayashi, J.; Kubota, T. Bioactive macrolides and polyketides from marine dinoflagellates of the genus Amphidinium. *J. Nat. Prod.* **2007**, *70*, 451–460.

23. Skropeta, D. Deep-sea natural products. *Nat. Prod. Rep.* **2008**, *25*, 1131–1166.

24. Pathom-aree, W.; Stach, J.; Ward, A.; Horikoshi, K.; Bull, A.; Goodfellow, M. Diversity of actinomycetes isolated from Challenger Deep sediment (10.898 m) from the Mariana Trench. *Extremophiles* **2006**, *10*, 181–189.

25. Prieto-Davo, A.; Fenical, W.; Jensen, P.R. Comparative actinomycete diversity in marine sediments. *Aquat. Microb. Ecol.* **2008**, *52*, 1–11.

26. Colquhoun, J.A.; Heald, S.C.; Li, L.; Tamaoka, J.; Kato, C.; Horikoshi, K.; Bull, A.T. Taxonomy and biotransformation activities of some deep-sea actinomycetes. *Extremophiles* **1998**, *2*, 269–277.

27. Gärtner, A.; Wiese, J.; Imhoff, J.F. *Amphritea atlantica* gen. nov., *sp. nov.*, a gammaproteobacterium from the Logatchev hydrothermal vent field. *Int. J. Syst. Evol. Microbiol.* **2008**, *58*, 34–39.
28. Lang, G.; Wiese, J.; Schmaljohann, R.; Imhoff, J.F. New pentaenes from the sponge-derived marine fungus *Penicillium rugulosum*: structure determination and biosynthetic studies. *Tetrahedron* 2007, 63, 11844–11849.

29. Dengler, W.A.; Schulte, J.; Berger, D.P.; Mertelsmann, R.; Fiebig, H.H. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. *Anti-Cancer Drugs* 1995, 6.

© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).